Second Sight Appoints Pat Ryan Chief Operating Officer
Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of
implantable visual prosthetics that are intended to create an artificial form of useful vision to blind patients, announced today
that Pat Ryan has been appointed Chief Operating Officer, effective immediately. In this newly created role, Mr. Ryan will assume
responsibility for Research & Development, Manufacturing, Planning & Materials, Quality Assurance, and Information
Technology. He will report to Will McGuire, Second Sight’s President and Chief Executive Officer.
“Pat brings a wealth of knowledge from both large and small medical device firms, and we are delighted to welcome him to the
Second Sight team. He has successfully led organizations in multiple regions of the world including COO roles at several public
medical device companies. Pat’s deep knowledge in manufacturing, quality assurance and R&D will be especially critical as
Second Sight continues to develop the Orion™ Cortical Visual Prosthesis System (Orion) and prepares for significantly higher
manufacturing volumes in future years,” said McGuire.
“Pat has the perfect background to ready Second Sight for an exciting future with Orion. His strong leadership in key areas will
be invaluable, as we move the Orion clinical and development programs forward and prepare for success in a market that includes
hundreds of thousands of potential patients worldwide,” said Gregg Williams, Chairman of the Board.
Mr. Ryan’s previous roles include serving as Chief Operations Officer at Synaptive Medical, and Chief Operating Officer at
Lucerno Dynamics and Insulet Corporation. He also served as Chief Operating Officer and President, International, at Alphatec
Spine. Earlier in Mr. Ryan’s career, he held multiple leadership positions at Guidant and Abbott Vascular, including Divisional
Vice President of Worldwide Operations at Abbott Vascular as well as Vice President & Managing Director for Guidant’s
manufacturing facility in Ireland. Following his graduation from the United States Naval Academy with a Bachelor of Science degree
in Economics, Mr. Ryan served as an officer in the U.S. Navy. He then received a Master of Science degree in Petroleum Management
from the University of Kansas.
The Company recently completed enrollment of the first five subjects, ahead of schedule, with Orion at the Ronald Reagan UCLA
Medical Center (UCLA) and the Baylor College of Medicine in Houston (Baylor) as part of Second Sight’s early feasibility clinical
study. All five subjects have had their Orion systems activated, and all subjects reported seeing light from virtually all
electrodes and stimulation parameters are within expected ranges. As a result of these successes, the Company is now progressing
with more complex testing involving real-time video input. Over the coming months, Second Sight intends to collect additional
important clinical and performance data to support the safety and efficacy of this breakthrough device.
“I am thrilled to join Second Sight at this exciting time and to help the organization build on its significant achievements to
date. I look forward to working with Will and the rest of the team to scale the infrastructure and team necessary for the
commercial success of Orion, and to enhance shareholder value,” said Pat Ryan, Chief Operating Officer.
About Second Sight
Second Sight Medical Products, Inc. (NASDAQ:EYES) develops, manufactures and markets implantable visual prosthetics that are
intended to deliver useful artificial vision to blind individuals. A recognized global leader in neuromodulation devices for
blindness, the company is committed to developing new technologies to treat the broadest population of sight-impaired
individuals.
Second Sight’s Argus® II Retinal Prosthesis System is the only FDA and CE Mark approved device for treating retinitis
pigmentosa, with proven implant durability of multiple years. In 2016, the company published five year results. Today, several
Argus II devices have been implanted and operational in humans for more than 10 years. The company is developing the Orion™ I
Visual Cortical Prosthesis which is intended to provide useful artificial vision to individuals who are blind due to various
causes. The company’s U.S. headquarters are in Los Angeles, and European headquarters are in Lausanne, Switzerland. More
information is available at
www.secondsight.com.
About Retinitis Pigmentosa
Affecting one in 4,000 individuals worldwide, retinitis pigmentosa (RP) is a rare, inherited genetic disorder that damages
retinal cells called photoreceptors. Photoreceptors absorb and convert light into electrical signals sent to other retinal cells,
then through the optic nerve to the brain which processes them into images. Common early symptoms of RP, often experienced in
childhood, include difficulty seeing at night and lost peripheral vision. Later, the disease may lead to blurring of vision, tunnel
vision, loss of central vision or loss of the ability to see colors. In many cases, severe vision problems occur in early
adulthood. RP may impact an individual’s ability to perform essential tasks of daily living such as reading, driving, walking
without assistance, or recognizing faces and objects.
About the Argus II Retinal Prosthesis System
The Argus® II Retinal Prosthesis System is an established, FDA and CE mark approved retinal implant that delivers a
useful form of artificial vision to individuals who are blind due to severe to profound retinitis pigmentosa (RP). The Argus II
works in place of lost photoreceptor cells and sends electrical pulses to remaining viable retinal cells to induce visual
perception. The system works by converting images captured by a miniature video camera mounted on glasses into a series of small
electrical pulses, which are transmitted wirelessly to an array of electrodes implanted on the surface of the retina. These pulses
stimulate the retina's remaining cells, enabling perception of patterns of light in the brain. The user learns to interpret these
visual patterns in order to regain some visual function. The Argus platform, which leverages the unique, patented design of its
60-contact array, is supported by more than 10 years of clinical experience and has been evaluated in multiple peer reviewed
publications. Argus II was also the first retinal neuromodulation prosthesis to receive widespread commercial approval and is
presently available at more than 50 leading medical centers in North America, Europe, the Middle East and Asia. Further information
on the long-term benefits and risks can be found in the peer reviewed paper at:
http://www.sciencedirect.com/science/article/pii/S0161642016305796.
About the Orion Visual Cortical Prosthesis System
Leveraging Second Sight’s 20 years of experience in neuromodulation for vision, the Orion™ Visual Cortical Prosthesis System is
an implanted cortical stimulation device intended to provide useful artificial vision to individuals who are blind due to a wide
range of causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, or forms of cancer and trauma. The Orion
System is intended to convert images captured by a miniature video camera mounted on glasses into a series of small electrical
pulses. The device is designed to bypass diseased or injured eye anatomy and to transmit these electrical pulses wirelessly to an
array of electrodes implanted on the surface of the brain’s visual cortex, where it is intended to provide the perception of
patterns of light. A feasibility study of the Orion I device is currently underway at the Ronald Reagan UCLA Medical Center in Los
Angeles and Baylor College of Medicine in Houston. No published in-human data is available yet for the Orion system. Based on the
results of this first in-human testing of the Orion I cortical stimulation device, the company anticipates initiation of the next
study in 2019.
Forward looking statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange and Exchange Act of 1934, as amended, which are intended to be covered by the
“safe harbor” created by those sections. All statements in this release that are not based on historical fact are “forward looking
statements.” These statements may be identified by words such as “estimates,” “anticipates,” “projects,” “plans,” “goal,” or
“planned,” “seeks,” “may,” “will,” “expects,” “intends,” “believes,” “should,” and similar expressions, or the negative versions
thereof, and which also may be identified by their context. All statements that address operating performance or events or
developments that Second Sight expects or anticipates will occur in the future, such as stated objectives or goals, or that are not
otherwise historical facts, are forward-looking statements. While management has based any forward-looking statements included in
this release on its current expectations, the information on which such expectations were based may change. Forward-looking
statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the
forward-looking statements as a result of various factors, including those risks and uncertainties described in the Risk Factors
and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our Annual Report, on Form
10-K, filed on March 20, 2018, our most recent 10-Q, filed on August 7, 2018, and our other reports filed from time to time with
the Securities and Exchange Commission. We urge you to consider those risks and uncertainties in evaluating our forward-looking
statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the
date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly
release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our
expectations with regard thereto, or any change in events, conditions, or circumstances on which any such statement is based.
Investor Relations:
Institutional Investors
In-Site Communications, Inc.
Lisa Wilson, 212-452-2793
President
lwilson@insitecony.com
or
Individual Investors
MZ North America
Greg Falesnik, 949-385-6449
Managing Director
greg.falesnik@mzgroup.us
or
Media:
Nobles Global Communications
Laura Nobles, 617-510-4373
Laura@noblesgc.com
or
Helen Shik, 617-510-4373
Helen@noblesgc.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20180904005269/en/